Janux Therapeutics, Inc.
$15.87
▲
2.27%
2026-04-21 07:38:00
www.januxrx.com
NGM: JANX
Explore Janux Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$962.36 M
Current Price
$15.87
52W High / Low
$35.34 / $12.12
Stock P/E
—
Book Value
$15.85
Dividend Yield
—
ROCE
-16.15%
ROE
-11.48%
Face Value
—
EPS
$-1.83
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
109
Beta
2.81
Debt / Equity
2.31
Current Ratio
39.04
Quick Ratio
39.04
Forward P/E
-4.28
Price / Sales
90.82
Enterprise Value
$-36.21 M
EV / EBITDA
0.23
EV / Revenue
-3.62
Rating
Strong Buy
Target Price
$54
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 2. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 3. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 4. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 5. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 6. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 7. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 10 M | 0 M | 0 M | 0 M |
| Operating Profit | -42.4 M | -35.25 M | -45.12 M | -34.9 M | -29.02 M |
| Net Profit | -31.95 M | -24.31 M | -33.86 M | -23.51 M | -20.22 M |
| EPS in Rs | -0.53 | -0.4 | -0.56 | -0.39 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10 M | 10.59 M | 8.08 M | 8.61 M |
| Operating Profit | -157.67 M | -98.85 M | -72.98 M | -67.09 M |
| Net Profit | -113.62 M | -68.99 M | -58.29 M | -63.06 M |
| EPS in Rs | -1.87 | -1.13 | -0.96 | -1.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1 B | 1.06 B | 380.41 M | 364.01 M |
| Total Liabilities | 44.74 M | 38.73 M | 36.06 M | 43.27 M |
| Equity | 956.82 M | 1.02 B | 344.35 M | 320.74 M |
| Current Assets | 975.89 M | 1.03 B | 349.24 M | 332.44 M |
| Current Liabilities | 25 M | 17.46 M | 13.03 M | 16.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -82.23 M | -43.81 M | -50.58 M | -42.92 M |
| Investing CF | -300.98 M | -258.02 M | -41.19 M | 58.27 M |
| Financing CF | 4.95 M | 713.24 M | 59.55 M | 0.5 M |
| Free CF | -83.28 M | -44.17 M | -52.42 M | -49.37 M |
| Capex | -1.04 M | -0.36 M | -1.85 M | -6.45 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 30.99% | -6.14% | — | — |
| Earnings Growth % | -18.36% | 7.56% | — | — |
| Profit Margin % | -651.62% | -721.18% | -732.22% | — |
| Operating Margin % | -933.58% | -902.87% | -779.04% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -914.12% | -878.68% | -769.28% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.